HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company specializing in cardiac monitoring, announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio(TM), company leadership, and institutional investors.
The proceeds will fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities, and general corporate purposes. This capital injection comes as the company seeks to bring its cable-free, 3D ECG technology to market, following FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025.
HeartBeam’s platform is designed to collect ECG signals in three non-coplanar directions and synthesize them into a standard 12-lead ECG, potentially allowing physicians to monitor cardiac health and detect acute conditions outside of medical facilities. The company holds over 20 issued patents related to its technology.
The offering underscores investor confidence in HeartBeam’s approach to cardiac care, which aims to reduce reliance on traditional, cumbersome ECG equipment. With the additional funding, the company expects to accelerate production and distribution of its devices, targeting both clinical and home-use markets.
For more details on the offering, visit https://ibn.fm/9iNYY. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
